Eturion

Raises HDL-C & lowers LDL/HDL & total cholesterol (total-C)/HDL ratios. Reduce total-C & LDL-C in adults w/ homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (eg, LDL apheresis). Reduce risk of MI in hypertensive adult patients w/o clinically evident CHD, but w/ at least 3 additional risk factors for CHD (eg, age ≥55 yr, male sex, smoking, left ventricular hypertrophy, other specified abnormalities on ECG, microalbuminuria or proteinuria, ratio of plasma total-C to HDL-C ≥6 or premature family history of CHD). Reduces risk of MI or stroke in adults w/ type 2 diabetes w/o clinically evident CHD, but w/ multiple risk factors for CHD (eg, retinopathy, albuminuria, smoking or HTN). Reduces risk of non-fatal MI, fatal & non-fatal stroke, revascularization procedures, hospitalization for CHF & angina in adults w/ clinically evident CHD. Adjunct to diet for reduction of elevated total cholesterol, LDL-C, apo B & triglycerides (TG) in adults, adolescents & childn ≥10 yr w/ primary hypercholesterolemia, heterozygous familial hypercholesterolemia or combined (mixed) hyperlipidemia (Fredrickson types IIa & IIb), elevated serum TG levels (Fredrickson type IV) & w/ dysbetalipoproteinemia (Fredrickson type III) when response to diet & other non-pharmacological measure is inadequate.

Initially 10 or 20 mg once daily. Patient who require large LDL-C (>45%) reduction Initially 40 mg once daily. Dose range: 10-80 mg once daily. Prevention of CVD Recommended dose: 10 mg once daily. Optimal dose may range to 10-80 mg once daily for secondary prevention. Primary hypercholesterolemia & combined (mixed) hyperlipidemia 10 mg once daily w/in 2 wk. Max: 4 wk. Homozygous familial hypercholesterolemia 80 mg. In combination w/ other medicinal compd (eg, cyclosporine, telaprevir or tipranavir/ritonavir) Max: 10 mg. In combination w/ elbasvir/grazoprevir Max: 20 daily. Childn ≥10 yr Recommended starting dose: 10 mg daily w/ titration up to 20 mg daily.

May be taken with or without food.

Hypersensitivity. Active liver disease or unexplained persistent elevations of serum transaminases >3 x ULN. Concomitant treatment w/ glecaprevir/pibrentasvir. Women of childbearing potential not using adequate contraceptive measures. Pregnancy & lactation.

Dyslipidaemic Agents

C10AA05 - atorvastatin ; Belongs to the class of HMG CoA reductase inhibitors. Used in the treatment of hyperlipidemia.

POM